Welcome to our dedicated page for Ultragenyx Pharmaceutical SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ultragenyx Pharmaceutical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ultragenyx Pharmaceutical's regulatory disclosures and financial reporting.
Ultragenyx (Nasdaq: RARE) filed an 8-K disclosing receipt of FDA Breakthrough Therapy Designation for GTX-102 (apazunersen) to treat Angelman syndrome.
The decision is supported by positive Phase 1/2 data in 74 children (ages 4-17) showing rapid, sustained and continuing developmental gains over up to three years.
Breakthrough status grants intensive FDA guidance, rolling review and potential priority review, which could materially shorten development timelines and lower regulatory risk.
The filing includes customary forward-looking statements covering clinical, regulatory and manufacturing uncertainties but announces no new financial terms.
Form 4 filing reveals insider trading activity at Ultragenyx Pharmaceutical (RARE) by Director Corazon (Corsee) D. Sanders. On June 20, 2025, Sanders executed a significant sale of company shares:
- Disposed of 2,405 shares at a price of $37.39 per share
- Transaction value: approximately $89,873
- Retained ownership: 15,344 shares held directly
This insider sale represents a notable reduction in Sanders' direct holdings in Ultragenyx. The transaction was executed as a standard sale (transaction code 'S') and was reported within the required SEC filing deadline. No derivative securities transactions were reported in this filing.
Ultragenyx Pharmaceutical Inc. (RARE) has filed a Form 144 with the U.S. Securities and Exchange Commission to notify the market of a proposed secondary sale of its equity.
- Securities: 2,405 shares of common stock
- Acquisition date & type: Restricted stock received on 05/15/2025 from the issuer
- Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004
- Planned sale date: Approximately 06/20/2025 on the NASDAQ exchange
- Estimated market value: US $89,922.95
- Total shares outstanding: 94,542,035 ⇒ proposed sale equals roughly 0.0025% of shares outstanding
- Prior 3-month sales: None reported
The filing is marked as LIVE and contains the standard representation that the seller is unaware of any undisclosed material adverse information. No additional financial data or strategic developments are included in this notice. Given the very small size of the transaction relative to Ultragenyx’s share base, the filing appears routine with limited market impact.